Stockscreener 앱 받기
19.76
1.02%
0.20
시장 영업 전:
19.99
0.23
+1.16%
전일 마감가:
$19.56
열려 있는:
$20
하루 거래량:
1.33M
Relative Volume:
0.93
시가총액:
$2.45B
수익:
$181.74M
순이익/손실:
$-599.49M
주가수익비율:
-3.9441
EPS:
-5.01
순현금흐름:
$-604.32M
1주 성능:
+9.47%
1개월 성능:
+1.59%
6개월 성능:
-30.18%
1년 성능:
-41.45%
1일 변동 폭
$19.57
$20.48
1주일 범위
$18.29
$20.48
52주 변동 폭
$17.05
$36.72
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
19.76 | 2.45B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
FDA accepts Arrowhead's NDA for plozasiran - MSN
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment - MarketWatch
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Arrowhead Pharmaceuticals director sells shares totaling $121,555 ate«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.33 - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2%Should You Buy? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Sells $578,426.88 in Stock - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 Shares - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares - MarketBeat
Arrowhead Pharmaceuticals COO sells shares worth $736,058 By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock - Investing.com
Arrowhead Pharmaceuticals COO sells shares worth $736,058 - Investing.com
Arrowhead Pharmaceuticals CFO Kenneth Myszkowski sells $893,095 in stock By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $219,456 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CEO sells $219,456 in stock - Investing.com India
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $219,456.00 in Stock - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.5%Should You Sell? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by JPMorgan Chase & Co. - MarketBeat
B. Riley Has Strong Forecast for ARWR FY2025 Earnings - MarketBeat
(ARWR) Investment Analysis - Stock Traders Daily
Principal Financial Group Inc. Sells 133,772 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Adeoye Y. Olukotun Sells 2,850 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock - MarketBeat
Insider Sell: Adeoye Olukotun Sells Shares of Arrowhead Pharmaceuticals Inc - GuruFocus.com
Arrowhead Pharmaceuticals director sells $57,000 in stock By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals CEO sells $246,109 in stock - Investing.com India
Arrowhead Pharmaceuticals CEO sells $246,109 in stock By Investing.com - Investing.com Australia
Christopher Richard Anzalone Sells 12,563 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock - MarketBeat
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - Simply Wall St
Arrowhead Pharmaceuticals, Inc. Announces Retirement of Douglass Given as Director, Effective December 31, 2024 - Marketscreener.com
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Launches Promising Phase 1/2a Obesity Drug Trial with Novel RNAi Therapeutic - StockTitan
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Geode Capital Management LLC - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 26,712 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals CEO sells $567,485 in stock By Investing.com - Investing.com UK
Ionis To Get Head Start On Arrowhead With Tryngzola Launch - News & Insights
HC Wainwright Reaffirms "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Ionis notches Arrowhead win; Tryngolza cleared for FCS - BioWorld Online
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by StockNews.com to "Sell" Rating - MarketBeat
Arrowhead Pharma Approves Major Employee Stock Grants, Expands Workforce with 20 New Hires - StockTitan
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Arrowhead Pharmaceuticals director sells shares totaling $121,555 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals director sells shares totaling $121,555 - Investing.com India
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 Shares - MarketBeat
Arrowhead Pharmaceuticals director sells $164,665 in stock - Investing.com India
Arrowhead Pharmaceuticals director sells $164,665 in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):